

SUPPORT FOR THE AMENDMENTS

The specification has been amended to replace the Abstract. Newly-added Claims 38-69 are supported by the specification, in particular page 23 in the last paragraph. No new matter is believed to have been added to the present application by the amendments submitted above.

REMARKS

Claims 38-69 are now pending. Favorable reconsideration is respectfully requested.

The present invention relates to an amphipathic glycopeptide, the amino acid sequence of which comprises an N- terminal opioid message sequence, a C-terminal helical address sequence, and a linker sequence between the message sequence and the helical address sequence, where

the C-terminal helical address sequence has a length of nine amino acids, and at least one of the amino acid residues of the peptide is glycosylated.

See Claim 38.

The rejections of the claims under 35 U.S.C. §102 over Bulet et al., Konig et al., Wagstaff et al. or Schambye et al. are respectfully traversed. The cited references fail to disclose the claimed glycopeptides.

Claim 38 is based on Claim 2 and further specifies that C-terminal helical address sequence has a length of nine amino acids. Claim 2 was not rejected over Bulet et al., Konig et al., Wagstaff et al. or Schambye et al. Since Claim 38 is narrower than Claim 2, those references do not anticipate Claim 38 and claims dependent thereon. Accordingly, withdrawal of these grounds of rejection is respectfully requested.

The rejections of the claims under 35 U.S.C. §102 over Palian et al. is respectfully traversed. The cited references fail to disclose the claimed glycopeptides.

Palian et al. disclose glycopeptides containing a helical address segment. However, the minimum length of that segment is twelve amino acids. See the sequences described on pages 500 and 501 of the reference. There is no disclosure or suggestion of a helical address sequence having nine amino acids as claimed. Accordingly, this reference fails to disclose the claimed glycopeptides. Withdrawal of this ground of rejection is respectfully requested.

The rejection of the claims under 35 U.S.C. §102(a) over Egleton et al. are respectfully traversed. Egleton is not available as prior art against the claims of the present application. The executed Rule 132 Declaration submitted herewith establishes that Robin Polt and Edward Bilsky are the inventors of the subject matter described in Egleton et al. See paragraphs 4-6 of the Declaration. Accordingly, Egleton et al. does not qualify as prior art against the present application under 35 U.S.C. §102(a). Withdrawal of this ground of rejection is respectfully requested.

The rejection of the claims under 35 U.S.C. §112, second paragraph, is believed to be obviated by the amendments submitted above. The issues raised in the Office Action have been addressed in the newly-added claims. In view of the foregoing, the claims are definite within the meaning of 35 U.S.C. §112, second paragraph.

Since the elected species is allowable as discussed above, search and examination should automatically be extended to the non-elected species.


Applicants submit that the present application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/03)



James J. Kelly, Ph.D.
Attorney of Record
Registration No. 41,504